Of the 28 patients with residual invasive component on the surgical specimen, only 1 (luminal B HER2+ with residual IDC + DCIS) was considered a false negative on both evaluations (CE only and CE + calcifications) due to the lack of residual enhancement and 5 cm of stable indeterminate calcifications (Supplementary Figure S3). Here, ERBB2 is linked to ductal breast carcinoma in situ.